A single-dose, randomized, two-period, two-sequence, crossover pilot bioequivalence study on formulations containing rivaroxaban and acetylsalicylic acid in healthy volunteers under fasting conditions.

2023-509841-12-00 Protocol 01/2023/Pozlab Human pharmacology (Phase I) - Bioequivalence study Ended

Start 28 Feb 2024 · End 18 Mar 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 01/2023/Pozlab

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 14
Countries 1
Sites 1

increased blood clotting

Key facts

Sponsor
Cepha s.r.o., Pozlab Sp. z o.o.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
28 Feb 2024 → 18 Mar 2024
Decision date (initial)
2024-02-05
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

increased blood clotting

VersionLevelCodeTermSystem organ class
20.0 PT 10002383 Angina pectoris 100000004849

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Cepha s.r.o.

Sponsor organisation
Cepha s.r.o.
Address
Komenskeho 19, Severni Predmesti Severni Predmesti
City
Plzen 1
Postcode
323 00
Country
Czechia

Scientific contact point

Organisation
Pozlab Sp. z o.o.
Contact name
Malgorzata Gurynowicz

Public contact point

Organisation
Pozlab Sp. z o.o.
Contact name
Maria Łaciak

Pozlab Sp. z o.o.

Sponsor organisation
Pozlab Sp. z o.o.
Address
Ul. Parkowa 2
City
Poznan
Postcode
60-775
Country
Poland

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 14 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Cepha s.r.o.
clinic, Komenskeho 19, Severni Predmesti, Plzen 1

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2024-02-28 2024-03-18 2024-02-28 2024-03-07

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-19 Czechia Acceptable
2024-02-05
2024-02-05